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Background: Preclinical and clinical studies have demonstrated a reduction of restenosis by drug coated balloons (DCB). The AngioSculpt Scoring 
Balloon (SC) is associated with improved acute results and a low rate of dissections. A drug coated SC (DCSC) might facilitate drug delivery to the 
vessel wall. The aim of the present study was to investigate the effect of varying the DCSC dose on safety and efficacy in porcine coronary arteries.
Methods: Applying modest balloon overstretch (~1.2:1), the left anterior descending and circumflex coronary arteries of 37 domestic pigs were 
treated with 60 sec inflations of uncoated SC and DCSC with a paclitaxel dose of 1.5, 3, 6, and 2x6 μg/mm2 followed by a bare metal stent. 
Quantitative coronary angiography (QCA) and histomorphometry was performed at 28 days.
Results: QCA revealed similar baseline angiographic parameters in all groups. At 28 d follow-up, late lumen loss was significantly reduced by all 
dosages of DCSC compared to uncoated SC. The smallest neointimal area was observed with 2x6μg/mm2, however this was not significantly different 
than 1.5 μg/mm2. There was no evidence of increased local toxicity including the highest dose group.
 
Conclusion: DCSC cause a consistent and reproducible inhibition of neointimal formation in the porcine coronary stent overstretch model. These 
results support the safety and efficacy of the dose range and type of coating proposed for a first in human clinical evaluation. 
